A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

Head and neck squamous cell carcinoma (HNSCC) commonly has an inflamed phenotype with T-cell infiltration that may benefit from immunotherapy. Durvalumab, a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, showed encouraging antitumor activity in many tumor types, including recurrent or metastatic (R/M) HNSCC in a phase 1/2 study (NCT01693562). Combining anti-PD-L1 and anti-CTLA-4 Abs showed enhanced preclinical antitumor activity over either agent alone, indicating that the 2 pathways are not redundant (Stewart et al.

http://ift.tt/2ImNKoE